Neoadjuvant Therapy
Neoadjuvant Therapy is a form of oncologic treatment that is administered before the primary local or definitive therapy (such as surgery or radiotherapy) to reduce tumor burden, improve resectability, and thereby enhance the overall efficacy of the treatment plan.
7.7K
Publications
498.1K
Citations
44.5K
Authors
5.4K
Institutions
Publications per year
2017–2026
3.3K
Variants
Neoadjuvant Treatment
7.7K
Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.6K citations
1–5 of 7.7K
44.5K
48
h-index
The University of Texas MD Anderson Cancer Center, United States
72 publications · 16.4K citations
47
h-index
45
h-index
44
h-index
42
h-index
1–5 of 44.5K
5.4K
The University of Texas MD Anderson Cancer Center
Houston, United States
124 h-index
3.3K publications
535.1K citations
Memorial Sloan Kettering Cancer Center
New York, United States
94 h-index
1.8K publications
305.2K citations
Dana-Farber Cancer Institute
Boston, United States
63 h-index
545 publications
52K citations
The Netherlands Cancer Institute
Amsterdam, The Netherlands
62 h-index
846 publications
89.2K citations
Harvard University
Cambridge, United States
58 h-index
715 publications
92.4K citations

Johns Hopkins University
Baltimore, United States
55 h-index
817 publications
169.4K citations

Institut Gustave Roussy
Villejuif, France
55 h-index
342 publications
67.3K citations
Heidelberg University
Heidelberg, Germany
54 h-index
826 publications
69.7K citations
1–8 of 5.4K
586 publications · 75.9K citations
136
h-index
406 publications · 23.9K citations
81
h-index
214 publications · 18.7K citations
75
h-index
181 publications · 16.8K citations
74
h-index
120 publications · 15.9K citations
63
h-index
1–5